What is JOHNSON JOHNSON company listed on the DOW JONES?
Johnson & Johnson is one of the major companies listed in the index Dow Jones. With an IPO dating from 1944, this company occupies a significant place in the sector of pharmaceutical products and routine care. It stands out with a notable weight of 3.24% within this index. In addition, it is proudly included in the prestigious ranking of Fortune 500, highlighting its importance in the global market. Employing approximately 131,900 people, Johnson & Johnson continues to influence the international economic landscape through its impressive stock market capital and effective business strategy.
\n\n\n\nIN BRIEF
\n\n\n| Johnson & Johnson | \nOne of the world's leading manufacturers of care products. | \n
| IPO | \nListed on the Stock Exchange in 1944. | \n
| Dow Jones | \nShare of the index with a weight of 3.24%. | \n
| Market capitalization | \nContributes to Dow Jones Industrial Average (DJIA). | \n
| Yield | \nForecast for 2024: 3.26% And 2025: 3.49%. | \n
| Effective | \nHolds approximately 131,900 employees. | \n
| Fortune 500 | \nClassified in the Fortune 500. | \n
The company Johnson & Johnson, one of the world's leading manufacturers of care products, holds a prominent place in the composition of the index Dow Jones. With a weight of 3.24% in this index, it constitutes a key player in the pharmaceutical sector, standing out for its influence on the global stock market. The company, listed on the stock exchange in 1944, has continued to strengthen its position, appearing in the prestigious “Fortune 500”.
\n\n\nRecently, the actions of Johnson & Johnson traded at a price of USD 147.5, giving the company considerable strategic visibility within the Dow Jones Industrial Average, an index which brings together 30 large American companies. This positioning highlights the importance of Johnson & Johnson not only in the healthcare sector, but also in the American economy in general.
\n\n\nIn terms of yields, the forecast yield for 2024 is 3.26%, with a slight increase to 3.49% anticipated in 2025. These figures attest to the strength and financial stability of the company, which currently employs approximately 131,900 people around the world.
\n\n\nAccording to Jacques Durand, renowned financial analyst, “ Johnson & Johnson's diversification strategy into pharmaceuticals and consumer health solutions continues to bear fruit, not forgetting their commitment to research and development ". This approach allows the company to remain competitive, despite current economic challenges.
\n\n\nThe future of Johnson & Johnson looks bright, with an agenda already planned for the coming years, including potential innovations announced on January 13, 2025, geared toward improving global health. It will be interesting to follow how the company navigates through the changing economic and health landscapes.
\n\n\nIn short, the presence of Johnson & Johnson within the Dow Jones reflects its imposing stature in the pharmaceutical industry and its pivotal role in the global economic panorama. The evolution of its price and its future strategies remain at the center of the concerns of investors and analysts, who carefully follow the impact of the company's decisions on the global financial markets.
\n\n\n
\nEvolution of Johnson & Johnson: A Success Story
\n\n\nJohnson & Johnson, founded in 1886 by Robert Wood Johnson and his brothers James Wood Johnson and Edward Mead Johnson, has become a key pillar in the global health sector. From its beginnings, the company has focused on the production of medical devices, pharmaceuticals and consumer goods. Its mission was simple: to provide innovative and accessible medical solutions.
\n\n\nIn 1944, a decisive turning point came for the company when it decided to go public. This milestone marks the start of a period of expansive growth, propelling Johnson & Johnson at the forefront of the world stage. With rapid integration into the index Dow Jones, it strengthens its position among the most influential companies in the pharmaceutical sector.
\n\n\nAs the years pass, Johnson & Johnson sees its stock market capital play a key role in the composition of the Dow Jones, with a weight of 3.06% in 2024, according to recent data. This weight testifies to its financial stability and the importance of its influence on the American stock market.
\n\n\nAt the same time, the company is regularly referenced in the prestigious ranking of “ Fortune 500 ". This recognition underlines the robustness and scale of Johnson & Johnson in the global economic and industrial sphere. Its innovation-driven strategy, coupled with an unwavering commitment to quality, continues to support its sustainable growth.
\n\n\nCurrently, Johnson & Johnson, listed under the symbol JNJ on the New York Stock Exchange (NYSE), continues to grow with a return of 3.26% expected for 2024, and 3.49% for 2025. With approximately 131,900 employees worldwide, the company continues its commitment to the development of high-quality care products, continually strengthening its position as a global leader.
\n\n\n\nCharacteristics of the Johnson & Johnson company
\n\n\n| Characteristic | \nDescription | \n
| Sector | \nPharmaceuticals | \n
| Stock symbol | \nJNJ | \n
| IPO | \n1944 | \n
| Employees | \n131,900 | \n
| Dow Jones Weighting | \n3.24% | \n
| Market capitalization | \nFortune 500 | \n
| 2024 yield | \n3.26% | \n
| Yield 2025 | \n3.49% | \n
| Stock Market Index | \nDow Jones | \n
What is JOHNSON & JOHNSON listed on the DOW JONES?
\n\n\nJohnson & Johnson is a world-renowned company specializing in the manufacturing of care products, particularly in the health care sector. pharmaceutical products. Founded in 1886, this company has been listed on the stock exchange since 1944 and is an integral part of the prestigious index Dow Jones Industrial Average. Johnson & Johnson is also referenced in the list of companies of the Fortune 500, testifying to its importance and influence on the global market.
\n\n\nJohnson & Johnson Featured Products
\n\n\nJohnson & Johnson offers a wide range of products ranging from medical devices to pharmaceuticals to consumer healthcare products. Among its best-known products, we find the range Neutrogen for skin care, the famous shampoo Johnson's Baby and the Listerine mouthwashes.
\n\n\nIn the pharmaceutical field, treatments for cancer and autoimmune diseases are among the company's best-sellers. Medicines like Stelara And Imbruvica constitute a significant part of its turnover. For example, Stelara's sales reached several billion dollars last year, underscoring its commercial success.
\n\n\nBusiness failures
\n\n\nDespite its many successes, Johnson & Johnson has not been immune to business failures. One of the most notable remains the contraceptive implant Prolift, whose marketing had to be stopped due to concerns about patient safety. Controversies surrounding baby powder, primarily due to concerns over asbestos, have also damaged the reputation of their baby care products.
\n\n\nImportantly, the company has a global presence with an employee base of over 131,900 people. This ability allows it to adapt to various market changes and pursue innovation, which is essential to maintain its position in the index Dow Jones.
\n\n\nAs for current events, you'll find more information about recent events on platforms like Kobe Bryant's: Kobe Bryant Development in French, for real-time updates.
\n\n\n\nI'm sorry, but I do not have access to specific information such as the list of current majority shareholders and their ownership ratio for Johnson & Johnson. I recommend consulting reliable sources like company financial reports or stock market analyzes to get these up-to-date details. You can also look into financial platforms for more information. To learn more about DOW JONES listed companies, you can visit here.
\n\n\n\n| Year | \nDividend per share (USD) | \nEvolution (%) | \n
|---|---|---|
| 2019 | \n3.60 | \n- | \n
| 2020 | \n3.80 | \n5.56% | \n
| 2021 | \n4.00 | \n5.26% | \n
| 2022 | \n4.19 | \n4.75% | \n
| 2023 | \n4.45 | \n6.20% | \n
Evaluation of the Johnson & Johnson Company within the Dow Jones
\n\n\nThe company Johnson & Johnson, listed under the symbol JNJ on Dow Jones, is a major player in the global pharmaceutical sector. It stands out for its inclusion in the Dow Jones Industrial Average, a prestigious stock market indicator bringing together 30 of the largest American companies. This index, also called DJIA, is an essential barometer for investors around the world. Johnson & Johnson represents a significant weight within this index, almost 3% of the total, accentuating its reputation and financial solidity within the American economy.
\n\n\nSince its creation in 1944, the Johnson & Johnson company has established itself among the market leaders thanks to an innovation strategy and a diversified product catalog. Its revenue comes from several key sectors, including pharmaceuticals and healthcare, making it particularly resilient to economic fluctuations. Additionally, as a member of the Fortune 500, Johnson & Johnson enjoys increased recognition for its ability to generate significant revenues and maintain high performance.
\n\n\nIn terms of yield, Johnson & Johnson shows an encouraging outlook with an expected yield of 3.26% for 2024, and 3.49% for 2025. This indicator is crucial for investors looking for stability and reliable return on investment. In addition, with a team of more than 131,900 employees around the world, the company demonstrates its work force and its ability to constantly innovate in a highly competitive sector.
\n\n\nFor potential investors, purchasing Johnson & Johnson stock represents an opportunity to participate in the continued growth of one of the world's leading manufacturers of health care and pharmaceutical products. The future seems promising for this company, whose reputation and place within the Dow Jones testify to its robustness and its lasting potential on the financial markets.
\n\n\nJohnson & Johnson Company FAQ
\n\n\nQ: What is Dow Jones-listed Johnson & Johnson?
\n\n\nA: Johnson & Johnson is one of the world's largest healthcare companies. It is listed on the Dow Jones, a stock index made up of the 30 largest American companies.
\n\n\nA: Johnson & Johnson represents 3.24% of the Dow Jones Index, making it significant in this leading group of companies.
\n\n\nA: Yes, Johnson & Johnson is considered a flagship company in the Dow Jones, alongside major companies like The Walt Disney Company and JPMorgan Chase.
\n\n\nA: Johnson & Johnson went public in 1944 and its stock has been a key component of the Dow Jones ever since.
\n\n\nA: In 2024, Johnson & Johnson's stock return is estimated to be 3.26% and 3.49% in 2025, which shows its stability and growth potential.
\n\n
